Previous 10 | Next 10 |
2023-11-14 08:03:24 ET More on Intellia Therapeutics Intellia Therapeutics, Inc. (NTLA) Q3 2023 Earnings Call Transcript Intellia Therapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation Intellia Therapeutics: Massive OpEx Begin To Weigh On HAE Prospects ...
CAMBRIDGE, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative single-dose therapeutics leveraging CRISPR-based technologies, today announced that the European Commission (EC...
2023-11-10 16:50:48 ET Summary Beam Therapeutics Inc.'s valuation has declined, as its progress in identifying candidates to work with its base editing technology and moving them into the clinic has been slow. Beam's lead program for Sickle Cell Disease is way behind CRISPR Therap...
2023-11-09 15:15:08 ET More on Intellia Therapeutics Intellia Therapeutics, Inc. (NTLA) Q3 2023 Earnings Call Transcript Intellia Therapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation Intellia Therapeutics: Massive OpEx Begin To Weigh On HAE Prospects ...
2023-11-09 12:32:02 ET Intellia Therapeutics, Inc. (NTLA) Q3 2023 Earnings Conference Call November 09, 2023 08:00 A.M. ET Company Participants Ian Karp - SVP, IR and Corporate Communications John Leonard - President and CEO David Lebwohl - EVP and CMO Laura ...
2023-11-09 07:32:15 ET More on Intellia Therapeutics Intellia Therapeutics: Massive OpEx Begin To Weigh On HAE Prospects Intellia cleared to start Phase 3 trial for gene editing drug Seeking Alpha’s Quant Rating on Intellia Therapeutics Historical earn...
FDA cleared NTLA-2001 IND application for first in vivo CRISPR candidate to enter late-stage clinical development; on track to initiate the MAGNITUDE pivotal Phase 3 trial in patients with transthyretin (ATTR) amyloidosis with cardiomyopathy by year-end Clinical data presented from ov...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
2023-11-08 12:39:19 ET More on Intellia Therapeutics Intellia Therapeutics: Massive OpEx Begin To Weigh On HAE Prospects Intellia cleared to start Phase 3 trial for gene editing drug Intellia's gene editing therapy for hereditary angioedema gets PRIME status in EU ...
2023-11-03 15:23:43 ET More on XBI and IBB Biopharma Bounce-Back: From Policy Pains To Profitable Plains IBB: The Illness Of Idiosyncratic Risk Jefferies is bullish on XBI at around $70 for year-end and first quarter 2024 returns Citi turns cautious on pharma...
News, Short Squeeze, Breakout and More Instantly...
Intellia Therapeutics Inc. Company Name:
NTLA Stock Symbol:
NASDAQ Market:
Intellia Therapeutics Inc. Website:
CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that it awarded inducement grants on July 22, 2024 to its Executive Vice Pr...
2024-07-23 12:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...